• An Image

    Our teams, facility and working environment are geared towards making the innovation faster, efficient and successful.

  • An Image

    As a drug discovery incubator, IBS is armed with experience, scientific tools, computer aided drug designing, expertise in chemistry, analytical instrumentation, in-vitro pharmacology and ADME.

  • An Image

    Dedicated teams include the best and brightest talent trained at Indian/International elite universities for which achieving the scientific goals is the sole priority.


Our talented team is committed to the scientific endeavor. Our energy and commitment to thought-partnering in the creative pursuit of the discovery of new therapies is among our biggest assets.

Dhananjay Pendharkar

Dr. Dhananjay Pendharkar was appointed as Senior Director-Business Operations in December 2012. Before joining IBS, Dhananjay was Senior Director-Medicinal Chemistry at Sai Life Sciences from 2005 to 2012. He worked in Aurigene Discovery Technologies from 2002 to 2005. His first industrial assignment was in Wockhardt. Dhananjay received his PhD in organic chemistry from Pune University in 1997 in the area of natural product synthesis. He did his post-doctorate at University of Kentucky from 1998 to 2000.

Kakoli Mukherjee

Dr. Kakoli Mukherjee was appointed Director, Biology Services, in June 2015. She brings sixteen years of industry experience to leading discovery biology and partner biology support activities at IBS. Prior to joining IBS, she was at AstraZeneca, Novartis and Alkem Laboratories. Between 2013 and 2015, as the lead biologist in Alkem's nascent NCE effort, she led a team that worked on metabolic disease and cancer. In the short span of less than two years the group was able to demonstrate proof of concept with compounds targeting Cathepsin K in a preclinical model of osteoporosis. She was Biochemistry Team Leader and LGG coordinator with AstraZeneca, Bangalore, (2006-2013), where she and her team worked on the discovery of small molecule, anti-infectives. While working mainly in the area of neglected tropical diseases, her team was able to help discover multiple pre-clinical candidates with potential for use in TB and Malaria. One molecule, AZD5847, is currently in clinical trials for TB treatment. Prior to that, she was at NITD, Singapore (2003-2006) and Astra Zeneca, Bangalore (2001-2003) were she was on several drug discovery teams, leading to several project transitions from hit identification to lead optimization and preclinical candidate nomination. Kakoli received her PhD in Molecular Biology from CCMB, Hyderabad in 1999. She completed a postdoctoral fellowship at the Karolinska Institute, Stockholm, Sweden, (1998-2000) before joining the pharmaceutical industry.

Gaurav Sharma

Dr. Gaurav Sharma is the Head of Analytical operations and associated with IBS since Jan'2013. He is an analytical professional with around fifteen years of research experience in Method Development, Validation, Impurity profiling for APIs, conducting Bioavailability and Bio-equivalence studies, Solubility studies, Stability studies, Documentation procedures, compliance to cGLP guidelines and related quality systems. Prior to joining IBS, he was associated with Sai life Sciences, Pune for around three years where he worked as a Group Leader and had leaded a group of analytical scientists. Before Sai, he worked with many premium segment pharmaceutical and healthcare organizations in India as Jubilant, Fortis, Lupin etc. He obtained his Ph.D. degree from CCS University, Meerut in Analytical Chemistry and his Masters in Commercial Methods of Chemical Analysis from Gurukul Kangri University, Haridwar.

Arunika Singhal

Ms. Singhal is responsible for the financial management of the company. She has been associated with the company since 2011. She has over 8+ years of experience in finance and accounts. Prior to joining the company, she was employed with State Bank of India as Assistant Vice-President (Credit) in Mid-corporate finance. She is a qualified Chartered Accountant and holds a Bachelors degree in commerce from the University of Delhi.

Anup Barde

Dr. Anup Barde is working with IBS as an Associate Director since May'2013. He is the head of scale up group at IBS. Prior to IBS he worked with Sai Life Sciences Pune from 2007-2013 as Senior Director- Chemistry. Prior to Sai LifeSciences he has worked with Emcure Pharmaceuticals, Pune (2003-2007), USV Limited, Mumbai (2000-2003) and FDC Limited, Mumbai (1996-2000). He has extensive experience in scale-up of compounds from gram scale to technology transfer for manufacturing. He has supported the DMF filings for several APIs and has also supported the Pre-Approval Inspections for US-FDA approval. Anup completed his Masters in Organic Chemistry in 1992 from D.G. Ruparel College from Mumbai University and received his PhD in Organic Chemistry from Haffkine Institute, Mumbai in 1996.

Sreekanth A Ramachandran

Dr. Sreekanth Ramachandran is working as an Associate Director and associated with IBS since May'2014. He is lead medicinal chemist at IBS. Prior to joining IBS, he worked in the medicinal chemistry department of AstraZeneca, Bangalore (2010-2014) as a Research Scientist focused on the small molecule drug discovery of anti-infective mainly in the area of Neglected Tropical diseases delivering multiple pre-clinical candidates in Malaria. During 2006 to 2009, he worked as a Research Scientist at the Department of Medicinal Chemistry, NAEJA Pharmaceutical Inc., Edmonton, Canada and was involved in the discovery of a first-in-class beta-lactamase inhibitors. Sreekanth received his PhD in Organic Chemistry from NIIST(formerly RRL, Trivandrum) in 2003, subsequently conducted his postdoctoral fellowship at the University of Leipzig, Germany (2003-2004) followed by another postdoctoral stint at the University of Sherbrooke, Canada (2004-2006).

Brahmam Pujala

Dr. Brahmam Pujala is working as a Principal scientist and associated with IBS since September'2011. He is a lead medicinal chemist at IBS. Brahmam received his PhD in Medicinal Chemistry from NIPER (Mohali) in 2011. He has published 10 papers in peer reviewed journals and inventor of 6 patents. He has been involved in the discovery and development of multiple preclinical and clinical candidates in the field of oncology and metabolic diseases.